SCHEMBL14993194

SCHEMBL14993194

CC1=C(C(O)Cc2ccc(F)c(C(F)(F)F)c2)C(C)(C)CCC1

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 2/20 0.37
▸ EPHX1 P07099 1/20 0.36
▸ PTPN7 P35236 6/20 0.36
▸ DUSP3 P51452 6/20 0.36
▸ P2RX7 Q99572 2/20 0.35
▸ CXCR3 P49682 1/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ SOS1 Q07889 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14995197 0.84 AR (0.37) AREPHX1PTPN7DUSP3P2RX7
SCHEMBL14993790 0.80 HTR2A (0.47) EPHX1
SCHEMBL14992642 0.79 RARB (0.32) —
SCHEMBL14992777 0.75 POLB (0.36) —
SCHEMBL20440810 0.74 DUSP3 (0.38) DUSP3
SCHEMBL20440811 0.71 HIF1A (0.38) —
SCHEMBL14993660 0.71 PDE2A (0.37) —
SCHEMBL20942917 0.70 RXRA (0.35) —
SCHEMBL12813382 0.69 HSD11B1 (0.34) —
SCHEMBL5018902 0.68 AR (0.44) AREPHX1PTPN7DUSP3P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2785178-B1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS INC (US) 2019-05-01 — — EP claimed
US-20190023649-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS, INC. (US) 2019-01-24 — — US claimed
US-10040749-B2 Opsin-binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS INC. (US) 2018-08-07 — — US claimed
US-20150038574-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS, INC. (US) 2015-02-05 — — US claimed
EP-2785178-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE Bikam Pharmaceuticals, Inc. (US) 2014-10-08 — — EP claimed
WO-2013081642-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS, INC. (US) 2013-06-06 — — WO claimed
EP-2785178-B1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS INC (US) 2019-05-01 — — EP disclosed
US-20190023649-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS, INC. (US) 2019-01-24 — — US disclosed
US-10040749-B2 Opsin-binding ligands, compositions and methods of use BIKAM PHARMACEUTICALS INC. (US) 2018-08-07 — — US disclosed
US-20150038574-A1 Opsin-Binding Ligands, Compositions and Methods of Use BIKAM PHARMACEUTICALS, INC. (US) 2015-02-05 — — US disclosed
EP-2785178-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE Bikam Pharmaceuticals, Inc. (US) 2014-10-08 — — EP disclosed
WO-2013081642-A1 OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE BIKAM PHARMACEUTICALS, INC. (US) 2013-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038574-A1 Opsin-Binding Ligands, Compositions and Methods of Use CRYAB, CRYAA, PDE6C AR 3929/4885EPHX1 3829/4885PTPN7 1677/4885
US-10040749-B2 Opsin-binding ligands, compositions and methods of use CRYAB, CRYAA, PDE6C AR 3929/4885EPHX1 3829/4885PTPN7 1677/4885
US-20190023649-A1 Opsin-Binding Ligands, Compositions and Methods of Use CRYAB, CRYAA, PDE6C AR 3929/4885EPHX1 3829/4885PTPN7 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback